Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1994-10-20
2003-05-13
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S443000
Reexamination Certificate
active
06562862
ABSTRACT:
BACKGROUND OF THE INVENTION
Neuropeptide Y is a peptide present in the central and peripheral nervous systems. The peptide co-exists with noradrenaline in many neurons and acts as a neurotransmitter per se or synergistically together with noradrenaline. Neuropeptide Y-containing fibers are numerous around arteries in the heart, but are also found around the arteries in the respiratory tract, the gastrointestinal tract, and the genitourinary tract. Neuropeptide Y is also present in the cerebrum with effects on blood pressure, feeding, and the release of different hormones. Alterations in central concentrations of neuropeptide Y have been implicated in the etiology of psychiatric disorders.
Neuropeptide Y was discovered, isolated and sequenced about ten years ago from porcine brain as part of a general screening protocol to discover carboxy-terminal amidated peptides and was named neuropeptide Y due to its isolation form neural tissue and the presence of tyrosine as both the amino and carboxy terminal amino acid. Neuropeptide Y is a member of the pancreatic family of peptides and shares significant sequence homology with pancreatic polypeptide, and peptide YY.
Neuropeptide Y and the other members of its family of peptides all feature a tertiary structure consisting of an N-terminal polyproline helix and an amphiphilic &agr;-helix, connected with a &bgr;-turn, creating a hairpin-like loop, which is sometimes referred to as the pancreatic polypeptide (PP) fold. The helices are kept together by hydrophobic interactions. The amidated C-terminal end projects away from the hairpin loop.
Subsequent to its discovery neuropeptide Y was identified as being the most abundant peptide in the central nervous system with widespread distribution including the cortex, brainstem, hippocampus, hypotahlamus, amygdala, and thalamus as well as being present in the peripheral nervous system in sympathetic neurons and adrenal chromaffin cells.
Neuropeptide Y seems to fulfill the main neurotransmitter criteria, since it is stored in synaptic granules, is released upon electrical nerve stimulation, and acts at specific receptors. It is clear that neuropeptide Y is an important messenger in its own right, probably in the brain, where neuropeptide Y potently inhibits the activity of adenylate cyclase and induces an increase in the intracellular levels of calcium. Central injection of neuropeptide Y results in blood pressure changes, increased feeding, increased fat storage, elevated blood sugar and insulin, decreased locomotor activity, reduced body temperature, and catalepsy.
Neuropeptide Y (as well as its chemical relatives) acts upon membrane receptors that are dependent on guanine nucleotides, known as G protein-coupled receptors. G proteins are a family of membrane proteins that become activated only after binding guanosine triphosphate. Activated G proteins in turn activate an amplifier enzyme on the inner face of a membrane; the enzyme then converts precursor molecules into second messengers.
Neuropeptide Y appears to interact with a family of closely related receptors. These receptors are generally classified into several subtypes based upon the ability of different tissues and receptors to bind differnt fragments of neuropeptide Y and the closely related peptide YY. The Y1 receptor subtype appears to be the major vascular neuropeptide Y receptor. The Y2 receptor subtypes can also occur postjunctionally on vascular smooth muscle. The as-yet-unisolated Y3 receptor subtype appears to be neuropeptide Y-specific, not binding peptide YY. This receptor is likely to be present in the adrenal tissues, medulla, heart, and brain stem , among other areas. [For a review of neuropeptide Y and neuropeptide Y receptors, see. e.g., C. Wahlestedt and D. Reis, Annual Review of Pharmacology and Toxicology, 33:309-352 (1993)].
In view of the wide number of clinical maladies associated with an excess of neuropeptide Y, the development of neuropeptide Y receptor antagonists will serve to control these clinical conditions. The earliest such receptor antagonists were peptide derivatives. These antagonists proved to be of limited pharmaceutical utility because of their metabolic instability.
In essence, this invention provides a class of potent non-peptide neuropeptide Y receptor antagonists. By virtue of their non-peptide nature, the compounds of the present invention do not suffer from the shortcomings, in terms of metabolic instability, of known peptide-based neuropeptide Y receptor antagonists.
SUMMARY OF THE INVENTION
This invention encompasses methods for the treatment or prevention of a physiological disorder associated with an excess of neuropeptide Y, which method comprises administering to a mammal in need of said treatment an effective amount of a compound of Formula I
wherein
R
1
and R
3
are independently hydrogen,
or
wherein
Ar is optionally substituted phenyl;
R
2
is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 4891357 (1990-01-01), Karlra
patent: 5075321 (1991-12-01), Schreiber
patent: 5393763 (1995-02-01), Black et al.
patent: 5439931 (1995-08-01), Sales
patent: 5441965 (1995-08-01), Sall et al.
patent: 5445941 (1995-08-01), Yang
patent: 5447941 (1995-09-01), Zuckerman
patent: 5457113 (1995-10-01), Cullinan et al.
patent: 5457117 (1995-10-01), Black et al.
patent: 5462937 (1995-10-01), Cullinan et al.
patent: 5464845 (1995-11-01), Black et al.
patent: 5468773 (1995-11-01), Dodge et al.
patent: 5476862 (1995-12-01), Calnek et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5492926 (1996-02-01), Cullinan et al.
patent: 5492927 (1996-02-01), Gitter et al.
patent: 5508292 (1996-04-01), Sall et al.
patent: 5510370 (1996-04-01), Hock
patent: 5525624 (1996-06-01), Gitter et al.
patent: 5567713 (1996-10-01), Cullinana et al.
patent: 5574047 (1996-11-01), Bumol et al.
patent: 5578613 (1996-11-01), Bryant et al.
patent: 5578614 (1996-11-01), Bryant et al.
patent: 5686467 (1997-11-01), Bumol et al.
patent: 5688813 (1997-11-01), Sall et al.
patent: 5700815 (1997-12-01), Calnek et al.
patent: 4311870 (1994-10-01), None
patent: 0 659 428 (1994-12-01), None
patent: WO93/10113 (1993-05-01), None
patent: WO93/1074 (1993-06-01), None
Draper et al., “Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women”, Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., “Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Bryant et al., “Raloxifene is a Tissue Specific Estrogen Agonist”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., “In Vivo and In Vitro Metabolism of Raloxifene”, Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., “Multiple Binding Sites for the Anti-estrogen Raloxifene”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., “Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats”, Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., “DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats”, Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., “Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;” .Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., “Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;” The Endocrine Society, Abstract 1982.
Black et al., “Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice,” Life Sciences, 26:1980, 1453-1458.
Black et al., “Diffe
Bruns, Jr. Robert F.
Gehlert Donald R.
Howbert J. Jeffry
Lunn William H. W.
Boudreaux William R.
Criares Theodore J.
Eli Lilly and Company
Sales James J.
LandOfFree
Methods of inhibiting physiological conditions associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting physiological conditions associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting physiological conditions associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3036704